» Articles » PMID: 37435554

Importance of the Mean Rate of Pressure Change of the Pulmonary Artery (dP/dt Mean PA) in Patients with Pulmonary Arterial Hypertension

Overview
Journal Avicenna J Med
Publisher Thieme
Specialty General Medicine
Date 2023 Jul 12
PMID 37435554
Authors
Affiliations
Soon will be listed here.
Abstract

 Pulmonary arterial hypertension (PAH) is a rare disease of cardiopulmonary circulation characterized by elevated pressure in the pulmonary artery. The right-heart catheter is the gold standard for diagnosis, but there is interest in identifying additional prognostic indicators. The aim of this study was to examine the importance of the rate of pressure change of the pulmonary artery (dP/dt mean PA) in patients with PAH.  We retrospectively analyzed data from 142 patients with PAH (exclusively clinical group 1) and examined the statistical correlation of dP/dt mean PA with vascular, right ventricular, and clinical parameters. Data was collected mostly from the right heart catheterization and the transthoracal echocardiography at presentation.  dP/dt mean PA showed a significant correlation with systolic pressure of the pulmonary artery ( = 142,  = 56%,  < 0.001), pulmonary vascular resistance (  = 142,  = 51%,  < 0.001), the rate of pressure change in the right ventricle (  = 142,  = 53%,  < 0.001), and the right ventricular fractional area change (  = 110,  = 51%,  < 0.001). Receiver operating characteristic curve analysis showed that dP/dt mean PA had the highest prognostic value in predicting increase in the 6-minute walk test and decrease in the N-terminal-probrain natriuretic peptide after the initiation of PAH therapy, with an area under the curve of 0.73.  Our findings suggest that dP/dt mean PA may be a useful prognostic indicator in the treatment of patients with PAH, and further research is warranted to validate this parameter.

References
1.
Nakamura T, Uematsu M, Deyama J, Watanabe Y, Nakamura K, Kobayashi T . Pulmonary Vascular Resistance Is Associated With Brachial-Ankle Pulse-Wave Velocity and Adverse Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. J Card Fail. 2019; 25(9):725-732. DOI: 10.1016/j.cardfail.2019.02.019. View

2.
Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Heart J. 2015; 37(1):67-119. DOI: 10.1093/eurheartj/ehv317. View

3.
Lee H, Oh B . Aging and arterial stiffness. Circ J. 2010; 74(11):2257-62. DOI: 10.1253/circj.cj-10-0910. View

4.
Frost A, Badesch D, Barst R, Benza R, Elliott C, Farber H . The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest. 2010; 139(1):128-37. DOI: 10.1378/chest.10-0075. View

5.
Channick R, Simonneau G, Sitbon O, Robbins I, Frost A, Tapson V . Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001; 358(9288):1119-23. DOI: 10.1016/S0140-6736(01)06250-X. View